Saturday 17 October 2026
Export NPCE’s income statement to Excel — free account
NeuroPace, Inc.
NPCE Healthcare Medical Devices
In the quarter to June 2026, revenue grew 17.1%, EPS grew 30.8%, free cash flow fell 78.7% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.
12.24
0.54
−4.23%
Follow NPCE
| Dec '17 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | 5 | 3 | 4 | 4 | 5 |
P/E ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
— | — | — | (1.91) | (5.37) | (4.09) | (4.67) | (2.52) |
P/S ratio |
— | 0.16 | 0.16 | 3.71 | 0.78 | 3.86 | 4.08 | 5.05 |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | (81.19) | (19.65) | (4.19) | (10.41) | (12.04) | (15.14) | (13.13) |
Beneish M-Score |
— | — | 2.78 | (3.15) | 47.37 | (2.58) | (2.96) | (2.88) |
P/Operating CF |
— | (1.13) | (1.13) | (20.41) | (4.52) | (75.68) | (67.94) | 998.49 |
P/B ratio |
— | 0.00 | 0.00 | 2.28 | 1.02 | 12.24 | 40.67 | 26.55 |
Price to Tangible BV |
— | 0.00 | 0.00 | 2.28 | 1.02 | 12.24 | 40.67 | 26.55 |
EV/Sales |
— | 0.69 | 0.69 | 2.33 | 0.32 | 3.77 | 4.21 | 5.07 |
EV/EBITDA |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | (1.40) | (1.40) | (4.28) | (0.39) | (12.53) | (18.74) | (46.03) |
EV/FCF |
— | (1.39) | (1.39) | (4.22) | (0.39) | (12.42) | (18.42) | (44.69) |
Quick Ratio |
— | 0.15 | 4.84 | 13.19 | 7.73 | 4.85 | 4.33 | 4.25 |
Current Ratio |
— | 0.27 | 5.69 | 14.28 | 8.90 | 5.71 | 5.37 | 5.28 |
Net Debt/EBITDA |
— | (2.04) | (1.60) | 2.84 | 0.61 | 0.36 | (0.34) | 0.15 |
Debt/Assets |
0.00% | 209.35% | 94.48% | 37.32% | 46.37% | 52.91% | 62.89% | 55.78% |
Debt/Equity |
— | (0.34) | (0.36) | 0.68 | 1.52 | 2.76 | 7.43 | 3.09 |
Asset Turnover |
— | 3.51 | 1.07 | 0.48 | 0.37 | 0.59 | 0.79 | 1.00 |
Operating CF/Net income |
— | 0.84 | 0.89 | 0.68 | 0.78 | 0.60 | 0.66 | 0.51 |
Capex/Depreciation |
— | (0.16) | (0.02) | (0.68) | (1.15) | (0.38) | (0.15) | (0.15) |
Interest Coverage |
— | (2.32) | (1.14) | (3.20) | (5.42) | (3.19) | (2.46) | (2.19) |
| — | 21.63% | 17.52% | 97.08% | (86.96%) | (118.91%) | (189.35%) | (158.74%) | |
| — | (284.17%) | (63.02%) | (38.08%) | (38.02%) | (29.72%) | (26.83%) | (21.44%) | |
ROIC |
— | 0.00% | 0.00% | (191.03%) | (247.99%) | (152.27%) | (91.62%) | (60.58%) |
Return on Tangible Assets |
— | 55.43% | (53.38%) | (29.07%) | (53.62%) | (42.53%) | (40.37%) | (27.74%) |
Average Days of Receivables |
— | 59.40 | 74.49 | 57.28 | 59.99 | 68.70 | 58.70 | 53.59 |
Research and Development Expense of Revenue |
— | 49.48% | 38.15% | 40.30% | 48.21% | 31.76% | 29.60% | 27.89% |
Selling, General and Administrative Expense of Revenue |
— | 81.69% | 67.16% | 86.23% | 112.79% | 83.33% | 71.46% | 65.68% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 3.90% | 3.35% | 9.49% | 18.34% | 14.61% | 12.87% | 11.09% |
Graham Net Nets |
— | (23.78) | (23.78) | 0.43 | 0.52 | 0.02 | (0.02) | 0.01 |
Graham Number |
— | 0.00 | 1,386.21 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | (472.13%) | (472.13%) | (337.20%) | (133.33%) | (13.09%) | (8.49%) | (4.27%) |
Free Cash Flow Yield |
— | (313.93%) | (313.93%) | (14.91%) | (105.80%) | (7.86%) | (5.60%) | (2.24%) |
Revenue per Share |
— | 183.12 | 200.67 | 2.72 | 1.85 | 2.53 | 2.74 | 3.06 |
Operating CF per Share |
— | (123.95) | (105.41) | (1.48) | (1.50) | (0.76) | (0.62) | (0.34) |
Capex per Share |
— | (2.30) | (0.30) | (0.02) | (0.02) | (0.01) | (0.01) | (0.01) |
Free Cash Flow per Share |
— | (126.25) | (105.71) | (1.50) | (1.52) | (0.77) | (0.63) | (0.35) |
Cash per Share |
— | 25.22 | 185.75 | 6.96 | 3.15 | 2.57 | 1.81 | 1.87 |
Shareholders Equity per Share |
— | (640.66) | (721.13) | 4.43 | 1.41 | 0.80 | 0.28 | 0.58 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | (640.66) | (721.13) | 4.43 | 1.41 | 0.80 | 0.28 | 0.58 |
Free Cash Flow |
— | (25.49) | (21.67) | (24.96) | (37.47) | (19.87) | (18.25) | (11.34) |
Working Capital |
— | (54.89) | 44.97 | 123.52 | 86.74 | 76.49 | 66.18 | 76.26 |
Capital Expenditures |
— | (0.46) | (0.06) | (0.38) | (0.60) | (0.17) | (0.31) | (0.33) |
Net Current Asset Value |
— | (130.18) | (149.22) | 72.76 | 18.39 | 5.72 | (5.29) | 7.54 |
EV/EBIT |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
— | 0.01 | 0.00 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||
Depreciation/Fixed assets |
— | 3.53 | 7.39 | 0.93 | 0.49 | 0.45 | 1.90 | 1.94 |
Cash ROIC |
— | 31.82% | 38.09% | (10.45%) | (22.70%) | (13.80%) | (15.18%) | (8.16%) |
Accounts Receivable Turnover |
— | 5.13 | 5.71 | 5.84 | 6.25 | 6.61 | 6.35 | 7.26 |
Accounts Payable Turnover |
— | 11.35 | 11.73 | 10.10 | 7.39 | 7.72 | 7.88 | 8.81 |
Inventory Turnover |
— | 1.42 | 1.47 | 1.60 | 1.49 | 1.65 | 1.69 | 1.50 |
Average Days of Payables |
— | 31.37 | 31.88 | 42.81 | 60.16 | 49.20 | 51.78 | 35.54 |
Days of Inventory on Hand |
— | 274.41 | 232.08 | 243.02 | 272.12 | 236.61 | 234.57 | 270.89 |
Average Receivables |
— | 7.21 | 7.21 | 7.74 | 7.29 | 9.90 | 12.58 | 13.77 |
Average Payables |
— | 0.93 | 0.93 | 1.16 | 1.76 | 2.24 | 2.64 | 2.59 |
Average Inventory |
— | 7.40 | 7.40 | 7.37 | 8.77 | 10.46 | 12.30 | 15.14 |
Average Assets |
— | 10.55 | 38.52 | 94.76 | 123.83 | 110.88 | 101.15 | 100.11 |
Average Common Equity |
— | (138.59) | (138.59) | (37.16) | 54.14 | 27.72 | 14.33 | 13.52 |
Columns are period end dates